Arcus Biosciences Advances Phase 1 Study of AB521 in Cancer Treatment

Arcus Biosciences ((RCUS)) announced an update on their ongoing clinical study.

Arcus Biosciences is currently conducting a Phase 1 clinical study titled A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors. The study aims to assess the safety, tolerability, and pharmacokinetic profile of AB521, also known as casdatifan, both as a standalone treatment and in combination with other therapies for patients with clear cell renal cell carcinoma (ccRCC) and other solid tumors. This study is significant as it explores potential new treatment options for these challenging cancer types.

The interventions being tested include casdatifan, administered orally, either alone or in combination with cabozantinib or zimberelimab. These treatments are designed to target and manage advanced solid tumor malignancies, particularly ccRCC.

The study follows an interventional design with a non-randomized, sequential intervention model. There is no masking involved, meaning both researchers and participants know which treatment is being administered. The primary purpose of the study is treatment-focused, aiming to determine the optimal dosage and safety profile of the interventions.

The study began on October 26, 2022, and is currently recruiting participants. The last update was submitted on July 29, 2025, indicating ongoing progress. The primary completion and estimated study completion dates have not been disclosed yet, highlighting the study’s ongoing nature.

From a market perspective, this study update could positively influence Arcus Biosciences’ stock performance and investor sentiment, as successful results may lead to new treatment options in the oncology market. This development is crucial in the competitive landscape of cancer therapies, where innovation is key to maintaining a competitive edge.

The study is ongoing, and further details are available on the ClinicalTrials portal.